帕金森病患者血清铜蓝蛋白与纹状体多巴胺转运体密度:与123I-FP-CIT SPECT的比较
本研究纳入141例初诊患者(帕金森病107例、疾病对照34例),测定血清铜蓝蛋白、铜、铁、总铁结合力及铁蛋白,并与123I-FP-CIT SPECT纹状体、尾状核、壳核及后壳核特异性结合比值进行相关分析。结果发现,除铜蓝蛋白外两组血清指标无差异;症状持续>2年的帕金森病患者铜蓝蛋白低于疾病对照组,且铜蓝蛋白与纹状体、尾状核和壳核的特异性结合比值在症状持续>1年及>2年的亚组中呈显著相关。
要点
- 帕金森病与疾病对照组除铜蓝蛋白外,铜、铁、总铁结合力及铁蛋白均无差异。
- 症状持续>2年的帕金森病患者血清铜蓝蛋白为21.4 ± 3.4,低于疾病对照组的24.0 ± 3.8(P = 0.03)。
- 症状持续>1年及>2年的亚组中,血清铜蓝蛋白与纹状体、尾状核和壳核的特异性结合比值呈正相关。
核心结论
- 血清铜蓝蛋白降低与症状持续超过1年的帕金森病患者多巴胺转运体密度降低呈正相关。
研究设计与样本
- 研究为单中心研究(原文未明确中心数),共分析141例初诊患者,其中帕金森病组107例,疾病对照组34例;疾病对照组包括血管性假性帕金森综合征、特发性震颤或药物诱发性帕金森综合征患者。
主要发现
- 除铜蓝蛋白外,两组的血清标志物无差异。
- 症状持续>2年的帕金森病患者血清铜蓝蛋白为21.4 ± 3.4,低于疾病对照组的24.0 ± 3.8(P = 0.03)。
- 症状持续>1年的亚组中,血清铜蓝蛋白与纹状体、尾状核和壳核特异性结合比值相关(P = 0.01、P = 0.02、P = 0.02)。
- 症状持续>2年的亚组中,血清铜蓝蛋白与纹状体、尾状核和壳核特异性结合比值相关(P < 0.01、P < 0.01、P = 0.04)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: In patients with Parkinson disease (PD), decreased serum ceruloplasmin levels have been observed. This study investigated a correlation between serum ceruloplasmin-along with its related serum markers- and striatal presynaptic dopaminergic denervation measured with I-FP-CIT SPECT. METHODS: We analyzed a total of 141 de novo patients divided into 2 groups: the PD group (107 patients with PD) and the disease control group (34 patients with vascular pseudoparkinsonism, essential tremor, or drug-induced parkinsonism). Serum ceruloplasmin and related serum markers, such as copper, iron, total iron-binding capacity, and ferritin, were measured. Specific binding ratios of the striatum, caudate nucleus, putamen, and posterior putamen were obtained by I-FP-CIT SPECT. RESULTS: There was no difference in the serum markers, except for ceruloplasmin, between the 2 groups. Ceruloplasmin level was significantly lower in PD patients with longer symptom duration (>2 years) than in the disease control group (21.4 ± 3.4 vs 24.0 ± 3.8, P = 0.03). Serum ceruloplasmin had a significant correlation with specific binding ratios of the striatum, caudate nucleus, and putamen in a subgroup with longer symptom duration (P = 0.01, P = 0.02, P = 0.02, respectively, for the subgroup with symptom duration >1 year, and P < 0.01, P < 0.01, P = 0.04, respectively, for the subgroup with symptom duration >2 years). CONCLUSIONS: Decrease in serum ceruloplasmin had a positive correlation with a decrease in dopamine transporter density in PD patients with symptom duration of more than 1 year.
引用
- Song YS, Kim JM, Kim KJ, et al. Serum Ceruloplasmin and Striatal Dopamine Transporter Density in Parkinson Disease: Comparison With 123I-FP-CIT SPECT. Clin Nucl Med. 2017. PMID: 28632695. doi:10.1097/RLU.0000000000001734
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。